Welcome to our dedicated page for Applied Dna Scie news (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied Dna Scie stock.
The APDN news archive on Stock Titan covers the historical disclosures and announcements of Applied DNA Sciences, Inc., a biotechnology company that developed and commercialized polymerase chain reaction (PCR)-based technologies for DNA production and detection and later adopted a BNB-focused digital asset treasury strategy. During the period when it traded under the Nasdaq symbol APDN, the company issued news on operational restructuring, platform development, customer activity, and capital markets transactions.
Readers can review company updates describing the transition to a pure play provider of synthetic DNA and mRNA manufacturing solutions through its majority-owned subsidiary LineaRx, Inc., including the focus on its LineaDNA, LineaRNAP, and LineaIVT platforms. News items detail workforce reductions, the exit from DNA tagging and security products and services, the closure of Applied DNA Clinical Labs, and the consolidation of operations behind LineaRx to support advanced biotherapeutics and diagnostic applications.
The archive also includes announcements related to conference participation and scientific posters showcasing the LineaDNA and LineaIVT platforms, follow-on orders for LineaDNA from a global in vitro diagnostics manufacturer for use in a cancer diagnostic application, and engagements with mRNA-focused contract development and manufacturing organizations. Financial news covers quarterly results, non-GAAP metrics such as Adjusted EBITDA and monthly net cash burn, and commentary on cost optimization and capital allocation.
Later APDN news releases document the company’s initiation of a BNB-focused digital asset treasury strategy, private placement commitments to fund BNB acquisitions, and the planned change of its Nasdaq ticker from APDN to BNBX to reflect this strategic focus. These items describe agreements with Cypress LLC and Cypress Management LLC for digital asset management and advisory services, as well as the involvement of institutional and crypto-native investors. By following this archive, investors can trace how APDN evolved from a biotechnology-focused issuer into BNB Plus Corp. (BNBX) with a combined profile in nucleic acid production and digital asset treasury management.
Applied DNA Sciences (NASDAQ: APDN) is advancing its cotton genomics program, enabling forensic proof of cotton authenticity, particularly for Egyptian Giza 94 cotton. At a recent American Apparel event, the company showcased a methodology using genomics and isotopic analysis to ascertain the origin of cotton. They filed a provisional patent for a biomarker unique to Giza 94, which was confirmed through collaboration with Isotech Laboratories. This geoTyping™ assay could revolutionize supply chain traceability in the textile industry, addressing past issues of mislabeling.
Applied DNA Sciences, Inc. (NASDAQ: APDN) will release its fourth quarter and full fiscal year 2021 financial results on December 9, 2021, after market close. A conference call is scheduled for 4:30 p.m. ET that same day, where management will discuss the results. The company specializes in PCR-based DNA manufacturing and has developed the LinearDNA platform for diverse applications, including diagnostics and drug development. For more information, visit adnas.com.
Flora Growth Corp. (NASDAQ: FLGC) has signed a licensing agreement with Tonino Lamborghini to produce and distribute luxury cannabis beverages, focusing on North America and Colombia. The product line will feature CBD and CBG and utilize Applied DNA Sciences' molecular tagging technology for product verification. The market for CBD products is expected to grow to $20 billion by 2024, with beverages being a key segment. The first product launch is scheduled for Q1 2022, which aligns with Flora's strategy to expand its brand portfolio.
Applied DNA Sciences (NASDAQ: APDN) has announced its COVID-19 diagnostic strategy to address the Omicron variant. The Linea 2.0 COVID-19 Assay is set for submission to the New York Department of Health, improving upon the existing Linea 1.0 Assay. The Linea 1.0 Assay shows a unique double S-gene target failure, which may lead to false negatives for Omicron but allows reliable reflex testing. Validation data for Linea 2.0 indicate enhanced performance. The company remains committed to high-quality PCR testing amid the evolving virus landscape.
Applied DNA Sciences (NASDAQ: APDN) reported a surge in demand for its LinearDNA™ from diagnostic customers and a new order from a Contract Research Organization (CRO) specializing in cancer research. The company has noted an increase in CRO orders, indicating growing adoption for therapeutic DNA in cell and gene therapies. CEO Dr. James A. Hayward highlighted the potential for LinearDNA to disrupt existing plasmid DNA manufacturing methods, particularly amid the rising need for scalable, high-quality DNA in therapeutic applications. This shift positions Applied DNA favorably in the growing gene therapy market.
Applied DNA Sciences, Inc. (NASDAQ: APDN) announced a new study published in Molecular Therapy: Methods and Clinical Development demonstrating the use of its proprietary LinearDNA™ technology for manufacturing CAR19 T-cells. This research indicates that CAR T-cells produced using LinearDNA show equivalent efficacy to those made with traditional plasmid DNA, presenting a more cost-effective and efficient production method. The study highlights LinearDNA's advantages, including >99% purity without the need for typical purification processes, potentially accelerating CAR T-cell therapy development.
Applied DNA Sciences (NASDAQ: APDN) and CLEARED4 have launched an integrated platform to assist large employers in complying with OSHA's Emergency Temporary Standard (ETS) regarding COVID-19 vaccination and testing. This comprehensive solution offers vaccine status management and weekly pooled COVID-19 testing via Applied DNA's safeCircle platform. Employers must ensure compliance by January 4, 2022, for workforces of 100 or more. The platform is already in use by various educational institutes and businesses to streamline health verification and testing processes.
Applied DNA Sciences (NASDAQ: APDN) has submitted a request for Emergency Use Authorization (EUA) from the FDA for its Linea™ SARS-CoV-2 Mutation Panel, which detects four SARS-CoV-2 mutations. Three of these mutations (E484K, L452R, N501Y) are classified by the CDC as substitutions of therapeutic concern, potentially impacting monoclonal antibody treatment efficacy. The panel aims to serve as a rapid alternative to Next Generation Sequencing for identifying COVID-19 patients with these mutations, which have shown 100% concordance with NGS results.
Applied DNA Sciences (NASDAQ: APDN) announced a collaboration with Ganesha Ecosphere Ltd., India's largest recycled polyester fiber producer. The agreement allows Ganesha to use Applied DNA's CertainT® platform for traceability in its recycled polyester production. This partnership aims to enhance sustainability in the textile industry by verifying raw materials through Applied DNA’s proprietary SigNature® T-100 tracer system. Ganesha, established in 1994, has a production capacity of 118,800 metric tons per year and serves over 300 customers.
Applied DNA Sciences (NASDAQ: APDN) has launched its COVID-19 testing program, safeCircle™, at Sarah Lawrence College to monitor virus prevalence among its population of 2,000 individuals. This program complements the College’s vaccine mandate and features on-site sample collection with quick turnaround times for test results. Mike Munzer from Applied DNA emphasized the importance of testing in light of the Delta variant's transmissibility. The safeCircle program utilizes high-sensitivity pooled RT-PCR testing, aiming to enhance safety on campus.
FAQ
What is the current stock price of Applied Dna Scie (APDN)?
What is the market cap of Applied Dna Scie (APDN)?
